Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) shares, rose in value, with the stock price up by 6.47% to the previous day’s close as strong demand from buyers drove the stock to $1.24.
Actively observing the price movement in the recent trading, the stock is buoying the session at $1.16, falling within a range of $1.23 and $1.35. The value of beta (5-year monthly) is 0.493. Referring to stock’s 52-week performance, its high was $2.55, and the low was $0.58. On the whole, CMMB has fluctuated by -24.23% over the past month.
With the market capitalization of Chemomab Therapeutics Ltd ADR currently standing at about $23.29 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-02.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CMMB’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of CMMB currently trading nearly -9.17% and -28.17% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 37.78, while the 7-day volatility ratio is showing 8.81% which for the 30-day chart, stands at 10.35%. Furthermore, Chemomab Therapeutics Ltd ADR (CMMB)’s beta value is 0.60, and its average true range (ATR) is 0.14.
A comparison of Chemomab Therapeutics Ltd ADR (CMMB) with its peers suggests the former has fared considerably weaker in the market. CMMB showed an intraday change of 6.47% in today’s session so far, and over the past year, it grew by 69.88%%.
Data on historical trading for Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) indicates that the trading volumes over the past 10 days have averaged 89340.0 and over the past 3 months, they’ve averaged 353.31K. According to company’s latest data on outstanding shares, there are 18.86 million shares outstanding.
Nearly 12.13% of Chemomab Therapeutics Ltd ADR’s shares belong to company insiders and institutional investors own 12.86% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.27 million shares as on 2025-03-14, resulting in a short ratio of 0.31. According to the data, the short interest in Chemomab Therapeutics Ltd ADR (CMMB) stood at 144.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 29261.0. The stock has fallen by -31.77% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CMMB stock heading into the next quarter.
